---
title: "Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294858413.md"
description: "Wolfe Research analyst Rudy Li reaffirmed a Buy rating on Stoke Therapeutics (STOK) with a $40 price target, citing the successful completion of the Phase 3 EMPEROR trial for zorevunersen and a strong $420M cash position. The report highlights a clear path to an early 2028 launch, supported by upcoming regulatory milestones. Additionally, H.C. Wainwright maintained a Buy rating with a $50 target."
datetime: "2026-08-04T18:35:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294858413.md)
  - [en](https://longbridge.com/en/news/294858413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294858413.md)
generator: "portal-rs"
---

# Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch

In a report released yesterday, Rudy Li from Wolfe Research maintained a Buy rating on Stoke Therapeutics, with a price target of $40.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Rudy Li has given his Buy rating due to a combination of factors tied to Stoke Therapeutics’ lead asset and clinical execution. He views the fully enrolled Phase 3 EMPEROR trial for zorevunersen in Dravet syndrome, completed ahead of plan with no treatment discontinuations, as a strong sign of robust operational performance and trial integrity.

He also highlights the clear and relatively near-term regulatory and commercial timeline, with a pre-NDA meeting in 2H26, rolling U.S. submission starting in 1Q27, full data in 3Q27, and a targeted launch in early 2028, all underpinned by long-term extension safety and efficacy data. Combined with a solid cash position of about $420M that supports the company through these milestones, he believes sentiment and share momentum should improve as pivotal data and regulatory catalysts approach, justifying his Buy recommendation on STOK.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News](https://longbridge.com/en/news/296264806.md)
- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**